

**Press release – For immediate release**  
**May 15, 2019 – 5:45 PM CEST**  
*Translation for information purposes only*

## **Ongoing negotiations with the European Investment Bank to conclude a loan financing agreement including the issuance of Warrants (BSA)**

*This loan financing agreement will enable Median Technologies to accelerate its investment programs for its iBiopsy® imaging phenomics platform for the coming years*

**Sophia Antipolis, France** – Median Technologies (ALMDT:PA), The Imaging Phenomics Company®, announces the ongoing negotiations with the European Investment Bank (EIB) for the signature of a financial partnership which will enable the Company to accelerate its investment programs for its iBiopsy® imaging phenomics platform for the coming years.

The financing agreement will allow the Company to borrow up to 35 M€ in three tranches through loan over the coming years subject to achieving a set of agreed performance criteria.

The release of the first tranche of €15m will result in the allocation of 800,000 warrants and, in the event that the second tranche of €10m is called, the release of the second tranche would result in the allocation of 300,000 additional warrants, which exercise price should vary depending on criteria. The total amount of warrants could represent up to 8.3 % of the share capital.

Negotiations are in advanced stages however the implementation of this financing is still subject to successful completion of EIB's internal validation processes and compliance review and to a favorable vote regarding the issuance of the warrants by the Median Shareholders' Meeting scheduled for the end of June 2019.

Median Technologies will issue a complementary press release on the day of the final signature of the contract, which should take place early Q3, 2019.



**About Median Technologies:** Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions for medical image analysis and management in oncology trials and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a US subsidiary and another one in Shanghai, Median has received the label “Innovative company” by the BPI and is listed on Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). For more information: [www.mediantechologies.com](http://www.mediantechologies.com)

## Contacts

<b>Median Technologies</b> Emmanuelle Leygues Head of Corporate Communications +33 6 10 93 58 88 <a href="mailto:emmanuelle.leygues@mediantechnologies.com">emmanuelle.leygues@mediantechnologies.com</a>	<b>Press - ALIZE RP</b> Caroline Carmagnol Aurore Gangloff + 33 1 44 54 36 66 <a href="mailto:median@alizerp.com">median@alizerp.com</a>	<b>Investors - ACTIFIN</b> Ghislaine Gasparetto +33 1 56 88 11 11 <a href="mailto:ggasparetto@actifin.fr">ggasparetto@actifin.fr</a>
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------